Annual ROE
24.95%
+81.48%+144.14%
December 31, 2023
Summary
- As of February 8, 2025, SPRO annual return on equity is 24.95%, with the most recent change of +81.48% (+144.14%) on December 31, 2023.
- During the last 3 years, SPRO annual ROE has risen by +100.72% (+132.93%).
- SPRO annual ROE is now at all-time high.
Performance
SPRO ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
4.36%
-17.90%-80.41%
September 30, 2024
Summary
- As of February 8, 2025, SPRO quarterly return on equity is 4.36%, with the most recent change of -17.90% (-80.41%) on September 30, 2024.
- Over the past year, SPRO quarterly ROE has dropped by -27.66% (-86.38%).
- SPRO quarterly ROE is now -86.38% below its all-time high of 32.02%, reached on December 31, 2023.
Performance
SPRO Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
SPRO ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +144.1% | -86.4% |
| 3 y3 years | +132.9% | -86.4% |
| 5 y5 years | +159.9% | -86.4% |
SPRO ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +130.6% | -86.4% | +102.8% |
| 5 y | 5-year | at high | +130.6% | -86.4% | +102.8% |
| alltime | all time | at high | +100.5% | -86.4% | +101.4% |
Spero Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | 4.36%(-80.4%) |
| Jun 2024 | - | 22.26%(-28.4%) |
| Mar 2024 | - | 31.08%(-2.9%) |
| Dec 2023 | 24.95%(-144.1%) | 32.02%(-1219.6%) |
| Sep 2023 | - | -2.86%(-85.0%) |
| Jun 2023 | - | -19.10%(-61.4%) |
| Mar 2023 | - | -49.42%(-37.2%) |
| Dec 2022 | -56.53%(-30.6%) | -78.64%(-49.2%) |
| Sep 2022 | - | -154.69%(+6.2%) |
| Jun 2022 | - | -145.66%(+33.2%) |
| Mar 2022 | - | -109.34%(+31.9%) |
| Dec 2021 | -81.47%(+7.5%) | -82.90%(+22.8%) |
| Sep 2021 | - | -67.51%(-2.1%) |
| Jun 2021 | - | -68.95%(0.0%) |
| Mar 2021 | - | -68.95%(-12.7%) |
| Dec 2020 | -75.77% | -78.98%(-14.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | -92.74%(-3.7%) |
| Jun 2020 | - | -96.28%(+15.1%) |
| Mar 2020 | - | -83.62%(+39.0%) |
| Dec 2019 | -63.99%(+53.7%) | -60.15%(+44.1%) |
| Sep 2019 | - | -41.74%(+12.6%) |
| Jun 2019 | - | -37.06%(+1.7%) |
| Mar 2019 | - | -36.43%(-18.6%) |
| Dec 2018 | -41.64%(-74.7%) | -44.78%(-46.7%) |
| Sep 2018 | - | -83.98%(-34.0%) |
| Jun 2018 | - | -127.26%(-58.3%) |
| Mar 2018 | - | -305.48%(+268.8%) |
| Dec 2017 | -164.56%(-34.4%) | -82.84%(-43.3%) |
| Sep 2017 | - | -146.17%(+7.3%) |
| Jun 2017 | - | -136.21%(-28.6%) |
| Mar 2017 | - | -190.81%(+43.4%) |
| Dec 2016 | -250.67%(-95.2%) | -133.02% |
| Dec 2015 | -5180.61% | - |
FAQ
- What is Spero Therapeutics annual return on equity?
- What is the all time high annual ROE for Spero Therapeutics?
- What is Spero Therapeutics annual ROE year-on-year change?
- What is Spero Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Spero Therapeutics?
- What is Spero Therapeutics quarterly ROE year-on-year change?
What is Spero Therapeutics annual return on equity?
The current annual ROE of SPRO is 24.95%
What is the all time high annual ROE for Spero Therapeutics?
Spero Therapeutics all-time high annual return on equity is 24.95%
What is Spero Therapeutics annual ROE year-on-year change?
Over the past year, SPRO annual return on equity has changed by +81.48% (+144.14%)
What is Spero Therapeutics quarterly return on equity?
The current quarterly ROE of SPRO is 4.36%
What is the all time high quarterly ROE for Spero Therapeutics?
Spero Therapeutics all-time high quarterly return on equity is 32.02%
What is Spero Therapeutics quarterly ROE year-on-year change?
Over the past year, SPRO quarterly return on equity has changed by -27.66% (-86.38%)